Skip to main content

Coronavirus Infection

10
Pipeline Programs
26
Companies
22
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
2
0
2
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
250%
Small Molecule
125%
Vaccine
125%
+ 22 programs with unclassified modality

On Market (1)

Approved therapies currently available

Novartis
ILARISApproved
canakinumab
Novartis
subcutaneous2009
39M Part D

Competitive Landscape

19 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
CanakinumabPHASE_3Monoclonal Antibody
Sandoz
SandozAustria - Kundl
1 program
1
CanakinumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04510493Completed116Est. Aug 2021
Inovio Pharmaceuticals
4 programs
2
1
1
INO-4800Phase 2/31 trial
INO-4800Phase 1/21 trial
INO-4800Phase 11 trial
INO-4800Phase 11 trial
Active Trials
NCT05430958Withdrawn0Est. Mar 2024
NCT04336410Completed120Est. Feb 2022
NCT04447781Completed79Est. May 2022
+1 more trials
Biomed
BiomedAustralia - Sydney
1 program
1
Drug: NA-831Phase 2/31 trial
Active Trials
NCT04452565Unknown525Est. Dec 2023
Biocad
BiocadRussia - St. Petersburg
1 program
1
Low dose BCD-250 injectionPhase 1/21 trial
Active Trials
NCT05037188Terminated50Est. Apr 2022
Altimmune
AltimmuneMD - Gaithersburg
1 program
1
AdCOVIDPhase 11 trial
Active Trials
NCT04679909Completed92Est. Dec 2022
Vaxine
VaxineAustralia - Bedford Park
1 program
1
COVID19 vaccinePhase 1Vaccine1 trial
Active Trials
NCT04453852Completed40Est. Apr 2021
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
COVID-19 and Lactating MothersN/A1 trial
Fixed site standard of care testingN/A1 trial
Active Trials
NCT04558320Completed76Est. Sep 2021
NCT04673292Completed831Est. Jun 2023
Verona Pharma
Verona PharmaUK - London
2 programs
Nasopharyngeal swabN/A1 trial
Ensifentrine Dose 1PHASE_21 trial
Active Trials
NCT04324866Unknown300Est. Dec 2020
NCT04527471Completed45Est. May 2021
Vanda Pharmaceuticals
Vanda PharmaceuticalsWASHINGTON, DC
2 programs
WGS Analysis of COVID-19 Positive PatientsN/A1 trial
TradipitantPHASE_31 trial
Active Trials
NCT04353401Completed79Est. Mar 2022
NCT04326426Enrolling By Invitation300Est. Aug 2020
Karyopharm Therapeutics
2 programs
SelinexorPHASE_21 trial
SelinexorPHASE_21 trial
Active Trials
NCT04355676Withdrawn0Est. Aug 2020
NCT04349098Completed190Est. Oct 2020
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
SARS-CoV-2 Antibody AnalysisN/A
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
SARS-CoV-2 Antibody AnalysisN/A
MSD
MSDIreland - Ballydine
1 program
SARS-CoV-2 Antibody AnalysisN/A1 trial
Active Trials
NCT04596579Completed1,135Est. Jul 2021
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
prayerN/A
Rhythm Pharmaceuticals
1 program
prayerN/A1 trial
Active Trials
NCT04361838Terminated200Est. Apr 2021
Martin Pharmaceuticals
1 program
vv-ECMO + cytokine adsorptionN/A1 trial
Active Trials
NCT04385771Suspended80Est. Oct 2021
Sanofi
SanofiPARIS, France
1 program
Hydroxychloroquine SAR321068PHASE_11 trial
Active Trials
NCT04333654Terminated8Est. May 2020
FUJIFILM Pharma
FUJIFILM PharmaMA - Cambridge
1 program
FavipiravirPHASE_3Small Molecule1 trial
Active Trials
NCT04373733Completed502Est. Jun 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozCanakinumab
FUJIFILM PharmaFavipiravir
Vanda PharmaceuticalsTradipitant
BiomedDrug: NA-831
Inovio PharmaceuticalsINO-4800
Verona PharmaEnsifentrine Dose 1
Karyopharm TherapeuticsSelinexor
Karyopharm TherapeuticsSelinexor
BiocadLow dose BCD-250 injection
Inovio PharmaceuticalsINO-4800
Inovio PharmaceuticalsINO-4800
AltimmuneAdCOVID
VaxineCOVID19 vaccine
SanofiHydroxychloroquine SAR321068
Inovio PharmaceuticalsINO-4800

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 6,075 patients across 22 trials

Canakinumab in Patients With COVID-19 and Type 2 Diabetes

Start: Oct 2020Est. completion: Aug 2021116 patients
Phase 3Completed

Early Intervention in COVID-19: Favipiravir Verses Standard Care

Start: May 2020Est. completion: Jun 2021502 patients
Phase 3Completed

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Start: Apr 2020Est. completion: Aug 2020300 patients
Phase 3Enrolling By Invitation
NCT04452565BiomedDrug: NA-831

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Start: Jun 2022Est. completion: Dec 2023525 patients
Phase 2/3Unknown

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Start: Nov 2020Est. completion: Sep 20221,307 patients
Phase 2/3Terminated
NCT04527471Verona PharmaEnsifentrine Dose 1

Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19

Start: Sep 2020Est. completion: May 202145 patients
Phase 2Completed

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Start: Apr 2020Est. completion: Aug 20200
Phase 2Withdrawn

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

Start: Apr 2020Est. completion: Oct 2020190 patients
Phase 2Completed
NCT05037188BiocadLow dose BCD-250 injection

Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)

Start: Aug 2021Est. completion: Apr 202250 patients
Phase 1/2Terminated

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

Start: Jul 2020Est. completion: May 202279 patients
Phase 1/2Completed

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

Start: Oct 2022Est. completion: Mar 20240
Phase 1Withdrawn

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Start: Feb 2021Est. completion: Dec 202292 patients
Phase 1Completed
NCT04453852VaxineCOVID19 vaccine

Monovalent Recombinant COVID19 Vaccine

Start: Jun 2020Est. completion: Apr 202140 patients
Phase 1Completed
NCT04333654SanofiHydroxychloroquine SAR321068

Hydroxychloroquine in Outpatient Adults With COVID-19

Start: Apr 2020Est. completion: May 20208 patients
Phase 1Terminated

Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers

Start: Apr 2020Est. completion: Feb 2022120 patients
Phase 1Completed
NCT04673292Allergy TherapeuticsFixed site standard of care testing

Community Collaboration to Combat COVID-19 (C-FORWARD)

Start: Feb 2021Est. completion: Jun 2023831 patients
N/ACompleted
NCT04596579MSDSARS-CoV-2 Antibody Analysis

SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida

Start: Oct 2020Est. completion: Jul 20211,135 patients
N/ACompleted
NCT04385771Martin Pharmaceuticalsvv-ECMO + cytokine adsorption

Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation

Start: Sep 2020Est. completion: Oct 202180 patients
N/ASuspended
NCT04353401Vanda PharmaceuticalsWGS Analysis of COVID-19 Positive Patients

WGS Analysis of COVID-19 Positive Patients

Start: Aug 2020Est. completion: Mar 202279 patients
N/ACompleted
NCT04558320Allergy TherapeuticsCOVID-19 and Lactating Mothers

COVID-19 and Lactating Mothers

Start: Jul 2020Est. completion: Sep 202176 patients
N/ACompleted

The COVID-19 ICU PRAYER Study

Start: May 2020Est. completion: Apr 2021200 patients
N/ATerminated
NCT04324866Verona PharmaNasopharyngeal swab

Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy

Start: Apr 2020Est. completion: Dec 2020300 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
26 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.